Welcome to our dedicated page for Onconetix news (Ticker: ONCO), a resource for investors and traders seeking the latest updates and insights on Onconetix stock.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on men’s health and oncology, and its news flow reflects that dual emphasis. Company press releases and SEC reports describe a portfolio that includes Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under IVDR, and ENTADFI, an FDA-approved, once-daily pill for the treatment of benign prostatic hyperplasia (BPH). News items often highlight clinical data, regulatory context, and commercialization steps for these assets.
Investors following ONCO news can expect updates on oncology diagnostics, particularly prostate cancer detection, and on men’s health therapeutics. For example, the company has reported new clinical validation data for Proclarix presented at the European Association of Urology congress, detailing performance in large patient cohorts and its potential to reduce unnecessary biopsies. Such news provides insight into how Onconetix positions Proclarix within established diagnostic pathways that rely on PSA testing and risk calculators.
Onconetix news also covers strategic transactions and partnerships. The company has announced the acquisition of Proteomedix, licensing agreements between Proteomedix and Immunovia related to the PancreaSure pancreatic cancer test, and, more recently, a non‑binding letter of intent and a definitive merger agreement with Ocuvex Therapeutics, Inc., followed by a joint announcement of the merger’s mutual termination. These items illustrate how the company evaluates business combinations and licensing to expand or refine its focus.
Another recurring theme in ONCO news is capital markets and listing compliance. Press releases discuss PIPE financings involving Series D and Series E preferred stock and warrants, an equity line of credit with Keystone Capital Partners, and a 1‑for‑85 reverse stock split implemented to address Nasdaq minimum bid price requirements. Updates on Nasdaq notices, hearings, and subsequent positive decisions by a Nasdaq Hearings Panel provide context for the company’s efforts to maintain its listing on The Nasdaq Capital Market.
By monitoring the ONCO news feed on this page, readers can track developments in Proclarix clinical evidence, ENTADFI commercialization, licensing arrangements in oncology diagnostics, and the company’s financing and corporate actions as disclosed in press releases and related SEC filings.
Onconetix, Inc. (NASDAQ: ONCO) announced the approval of all proposals at its 2024 Annual Meeting of Stockholders held on September 5, 2024. The company's Board of Directors approved a 1-for-40 reverse stock split of its outstanding common shares, effective September 24, 2024. Key approvals include:
1) Election of two Class III directors
2) Increase in shares under the 2022 Equity Incentive Plan
3) Authorization for reverse stock split
4) Approval of share issuances related to Series A and B Preferred Stock conversions, private placement financing, and Proteomedix AG stock option assumption
5) Approval of share issuances for inducement preferred investment options and placement agent warrants
6) Ratification of EisnerAmper LLP as independent auditor
The reverse split aims to regain compliance with Nasdaq's minimum bid price requirement. It will reduce the number of outstanding shares from approximately 30.2 million to 755,000.
Onconetix (Nasdaq: ONCO) has closed the previously announced exercise of existing warrants, raising $1.11 million in gross proceeds. The company issued 7,458,642 shares of common stock at a reduced exercise price of $0.15 per share. In exchange, Onconetix issued new unregistered warrants to purchase up to 22,375,926 shares of common stock in a private placement.
The new warrants have an exercise price of $0.15 per share and are subject to stockholder approval. One-third of the warrants have a 5-year term, while two-thirds have a 24-month term from the date of stockholder approval. H.C. Wainwright acted as the exclusive placement agent for this transaction.
Onconetix announced the exercise of existing warrants, leading to gross proceeds of $1.11 million. The company agreed to lower the exercise price of warrants issued in August 2022 and 2023 from $1.09-$2.546 per share to $0.15 per share. This transaction, handled by H.C. Wainwright & Co., is anticipated to close by July 12, 2024. Proceeds will be used for working capital and corporate purposes. In return, Onconetix will issue new unregistered warrants for 22,375,926 shares at $0.15 per share, pending stockholder approval within 90 days. The new warrants will have varying exercise terms of 24 months and five years.
Summary not available.
Oncopeptides AB announced that Holger Lembrer has taken office as Chief Financial Officer (CFO) as of January 18, 2023. His appointment aims to enhance the company’s leadership team, bringing valuable expertise from his previous roles in publicly traded international companies. Oncopeptides focuses on developing therapies for difficult-to-treat hematological diseases, leveraging its proprietary Peptide Drug Candidate platform. Pepaxti, their notable product, has received marketing authorization in the EU and other regions for the treatment of adult patients with multiple myeloma, although it is not currently marketed in the US following a recommendation to withdraw its authorization.